The CBC, ordered hundreds of millions of times a year in the US alone, typically reports 19 different values, some of which are redundant and inconsequential. These authors suggest three distinct CBCs. [Subscription Required]

A prospective cohort study of 629 patients with non-MRI-conditional ICDs from 2003 to 2013, including 813 MRIs, concludes that the devices continue to function properly after MRI.

This 33-year-old man reports no other symptoms, and he isn’t on any medication. Medical history is unremarkable. CBC and comprehensive profile are normal, as are serum alpha-fetoprotein and beta-HCG. CT scans reveal bulky diffuse adenopathy. A cervical node biopsy showed poorly differentiated carcinoma. What is the appropriate therapy?

OBR covers this New York Times opinion piece; many doctors are jumping on the bandwagon to point out where the cause of burnout truly lies.

The Cancer Moonshot aims to enhance the lives of individuals and families dealing with and surviving cancer, lower the death rate from cancer by at least 50% over the following 25 years, and ultimately put an end to cancer as we currently know it. In order to mobilize the federal government, the President established the first-ever Cancer Cabinet last year. He urged people, healthcare professionals, and leaders from various sectors to step up and take action in five key priority areas: (1) close the screening gap; (2) comprehend and address environmental exposure; (3) lessen the impact of preventable cancers; (4) bring cutting-edge research through the pipeline to patients and communities; and (5) support patients and their care. Here is the list of 13 more initiatives to go along with the already-introduced 25 programs, policies, and resources to address these five priority areas.

Based on prior studies in patients with melanoma and lung cancer as well as overall response and duration of response rates in open-label, multiple cohort trials involving 131 adults and 36 children, the combination was approved for the new indication (treatment of unresectable or metastatic solid tumors with a BRAF V600E mutation in patients ≥6 years old who have progressed following prior treatment and have no satisfactory alternative treatment options). Adults with BRAF V600E mutation-positive solid tumors, such as low-grade glioma (LGG), anaplastic thyroid cancer, biliary tract cancer, small intestine cancer, and high-grade glioma (HGG), were enrolled in the new trials, along with 36 children with BRAF V600 refractory or recurrent LGG or HGG. The overall response rate (ORR) served as the trial’s main measure of success, and out of the 131 adults who participated, 54 (41%) had an objective reaction. Among the most prevalent tumor types in the clinical trials, the ORR for biliary tract cancer was 46%, HGG was 33%, and LGG was 50%. Children’s ORR was 25%.